July 28, 2026—Antimicrobial resistance (AMR) remains one of the most significant challenges facing health care today. According to global estimates, antimicrobial-resistant infections were associated with nearly 5 million deaths worldwide in 2019, while more than 2.8 million resistant infections occur annually in the United States. As resistance mechanisms continue to evolve and spread, clinical laboratories play an increasingly critical role in providing timely information that helps guide patient management and antimicrobial stewardship efforts.
Speed matters. Every hour spent waiting for critical resistance information can impact treatment decisions, infection control measures, and patient outcomes. While expensive molecular and automated technologies continue to advance, rapid lateral flow immunoassays have emerged as valuable tools that provide actionable results within minutes, require minimal hands-on time, and can be easily integrated into existing microbiology workflows, without the need to purchase additional equipment.
At ADLM 2026, Hardy Diagnostics will showcase a portfolio of rapid lateral flow assays designed to help laboratories identify important resistance mechanisms and emerging pathogens. These assays provide targeted information without the need for additional instrumentation, making them accessible and cost-effective solutions for laboratories of all sizes.
Among the featured products is the FDA-cleared NG-TEST CARBA 5, a rapid multiplex assay that simultaneously detects the five most clinically significant carbapenemase families: KPC, OXA-48-like, VIM, IMP, and NDM. Also on display is the FDA-cleared NG-TEST CTX-M Multi, which enables rapid detection of CTX-M enzymes associated with extended-spectrum beta-lactamase (ESBL) production.
Hardy Diagnostics will also feature NG-TEST Candida auris, the first commercially available lateral flow immunoassay for the detection of Candida auris in the United States. As health care facilities continue to monitor this emerging pathogen, rapid detection tools may play an important role in infection prevention strategies. NG-TEST Candida auris is currently available for research use only in the United States while FDA review continues.
In addition, visitors to Booth #3083 will have the opportunity to learn about NG-TEST Acineto-5, a rapid immunoassay designed to simultaneously detect and differentiate major carbapenemase families found in Acinetobacter species. NG-TEST Acineto-5 is available for research use only in the United States while FDA review continues.
As laboratories continue to face growing demands, staffing challenges, and increasing antimicrobial resistance, rapid diagnostic tools can help deliver the timely answers clinicians need. Hardy Diagnostics remains committed to providing innovative solutions that support microbiology laboratories in their mission to improve patient care and combat antimicrobial resistance.
This is promotional content provided by Hardy Diagnostics.